$CABA News

Cabaletta Bio Presents New Clinical Data Supporting Rese-Cel As Potential Treatment For Multiple Autoimmune Diseases, At EULAR 2026 Congress

Wells Fargo Maintains Equal-Weight on Cabaletta Bio, Raises Price Target to $4

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune

Cabaletta Bio Q1 EPS $(0.39), Inline

Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $30 Price Target

Cabaletta Prices Share Sale Of 51.73M Shares at $2.90 to Fund Autoimmune Therapy Development

Cabaletta Bio Announces Commercial Agreement With Cellares To Supply Rese-Cel Using Cellares' Automated Cell Shuttle To Enable Flexible Low-Cost Commercial Scaling

Cabaletta Bio Announces Commercial Agreement With Cellares To Supply Rese-Cel Using Cellares' Automated Cell Shuttle To Enable Flexible Low-Cost Commercial Scaling

Cabaletta Bio Reveals Multiple Upcoming Presentations, Including Data on Rese-Cel without Preconditioning and Rese-Cel with Automated Manufacturing, At The ASGCT 2026 Annual Meeting

Cabaletta Bio Doses First Two Patients Rese-cel Manufactured on Cellares' Automated Cell Shuttle Platform

Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13

Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16

Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate

Cabaletta Bio Highlights Pivotal Myositis Trial, No-Preconditioning CAR-T Push at TD Cowen Conference

Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know

Are Medical Stocks Lagging Biodesix (BDSX) This Year?

Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution

Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

Here’s Why Jacob Funds Established a Position in Cabaletta Bio (CABA)

Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA